Agile Therapeutics


William Tanner Cuts Price Target on Agile Therapeutics Inc (AGRX) But Believes Twirla Patch “Still Approvable”

Even though Cantor’s William Tanner slices his price target, he nonetheless angles for almost 115% whopping upside potential for AGRX shares.

We Continue To Believe That Shares Of Agile Hold A Strong Risk/Reward Profile, Says William Blair

In a research report released today, William Blair analyst Tim Lugo reaffirmed an Outperform rating on Agile Therapeutics (NASDAQ:AGRX) with an $18 price …

Janney Capital Reiterates Buy On Agile Therapeutics Following Initiation Of Phase III Twirla Study

In a research note released today, Janney Capital analyst Kimberly Lee reiterated a Buy rating on Agile Therapeutics (NASDAQ:AGRX) with an $18 fair value …